A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:35
|
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 12期
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
  • [31] Comparison of Treatment With Sitagliptin (SITA) or Sulfonylurea (SU) in Patients With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Insufficiency
    Engel, Samuel S.
    Xu, Lei
    Golm, Gregory T.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2013, 62 : A139 - A139
  • [32] Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus A meta-analysis of randomized controlled trials
    Feng, Miao
    Lv, Haihong
    Xu, Xia
    Wang, Jue
    Lyu, Wenyi
    Fu, Songbo
    MEDICINE, 2019, 98 (30)
  • [33] The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone
    Koutsovasilis, Anastasios
    Sotiropoulos, Alexios
    Pappa, Maria
    Papadaki, Despina
    Kordinas, Vasilis
    Tamvakos, Charalampos
    Bourikou, Maria
    Bousboulas, Stavros
    Peppas, Theodoros
    DIABETES, 2018, 67
  • [34] Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
    F. J. Lavalle-González
    A. Januszewicz
    J. Davidson
    C. Tong
    R. Qiu
    W. Canovatchel
    G. Meininger
    Diabetologia, 2013, 56 : 2582 - 2592
  • [35] Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
    Lavalle-Gonzalez, F. J.
    Januszewicz, A.
    Davidson, J.
    Tong, C.
    Qiu, R.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2013, 56 (12) : 2582 - 2592
  • [36] THE EFFICACY AND RENAL SAFETY OF SWITCHING FROM DAPAGLIFLOZIN TO EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, Ai-Yu
    Chen, Hung-Chun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1374 - 1374
  • [37] Long-term Efficacy and Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus
    Tada, Yuko
    Kanazawa, Ippei
    Notsu, Masakazu
    Tanaka, Ken-ichiro
    Kiyohara, Nobuaki
    Sasaki, Motofumi
    Sugimoto, Toshitsugu
    INTERNAL MEDICINE, 2016, 55 (10) : 1275 - 1278
  • [38] Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
    Zhaohu, Hao
    Xiao, Huang
    Hailin, Shao
    Feng, He
    JOURNAL OF DIABETES RESEARCH, 2022, 2022
  • [39] Efficacy and Safety of Sitagliptin Therapy Compared with Pioglitazone in Heart Failure Patients with Type 2 Diabetes
    Naka, Toshio
    Akagami, Takafumi
    Doi, Takashi
    Masuyama, Tohru
    Ohyanagi, Mitsumasa
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (10) : S188 - S188
  • [40] Randomized Controlled Trial of Ipragliflozin vs. Sitagliptin in Type 2 Diabetes Mellitus Patients
    Nakai, Kazuki
    Tsurutani, Yuuya
    Sugisawa, Chiho
    Saitou, Jun
    Omura, Masao
    Nishikawa, Tetsuo
    DIABETES, 2017, 66 : A335 - A335